Research Article
RBD targeted COVID vaccine and full length spike-protein vaccine (mutation and glycosylation role) relationship with procoagulant effect
Luisetto M*, Tarro G, Farhan Ahmad Khan, Khaled Edbey, Mashori GR, Ahnaf Ilman, Yesvi AR and Latyschev OY
Published: 04/26/2021 | Volume 5 - Issue 1 | Pages: 001-008
Abstract
Related COVID vaccine production many different strategies was followed by the producers.
Observing some rare event of thrombosis after some COVID-19 vaccination, it is interesting to verify if the Target used for the manufacturing can be involved in a different procoagulant activity or not.
Some vaccine are suspended in some country or under a deep new verify- investigation by the regulatory agency. (EU or USA).
This fact it is relevant.
The target SPIKE-PROTEIN FULL LENGTH modified or not or towards the RBD domain can be a relevant factor.
Read Full Article HTMLDOI: 10.29328/journal.jcavi.1001007Cite this Article
References
- Dai L, Gao GF. Viral targets for vaccines against COVID-19. Nat Rev Immunol. 2020; 21: 73–82. PubMed: https://pubmed.ncbi.nlm.nih.gov/33340022/
- Speiser DE, Bachmann MF. Vaccines COVID-19: Mechanisms of Vaccination and Immunity. Vaccines. 2020; 8: 404. PubMed: https://pubmed.ncbi.nlm.nih.gov/32707833/
- Prüβ BM. Review Current State of the First COVID-19 Vaccines. Vaccines 9010030. 2021; 9: 30. PubMed: https://pubmed.ncbi.nlm.nih.gov/33429880/
- Yang J, Wang W, Wei X. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity. Nature. 2020; 586: 572–577. PubMed: https://pubmed.ncbi.nlm.nih.gov/32726802/
- Liu Z, Xu W, Xia S, Gu C, Wang X, et al. RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response. Signal Transduct Target Ther. 2020; 5: 282. PubMed: https://pubmed.ncbi.nlm.nih.gov/33247109/
- Zhang S, Liu Y, Wang X, Yang L, Li H, et al. SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19. J Hematol Oncol. 2020; 13: 120. PubMed: https://pubmed.ncbi.nlm.nih.gov/32887634/
- Makowski L, Olson-Sidford W, Weisel JW. Biological and Clinical Consequences of Integrin Binding via a Rogue RGD Motif in the SARS CoV-2 Spike-protein. Viruses. 2021; 13: 146. PubMed: https://pubmed.ncbi.nlm.nih.gov/33498225/
- Brun J, Vasiljevic S, Gangadharan B, Hensen M, Chandran AV, et al. Analysis of SARS-CoV-2 spike glycosylation reveals shedding of a vaccine. 2020.
- Watanabe Y, Mendonça L, Allen RE, Howe A, Lee M, et al. Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222. Vaccine. 2021. PubMed: https://pubmed.ncbi.nlm.nih.gov/33501433/
- Ikegame S, Siddiquey MNA, Hung CT, Haas G, Brambilla L, et al. Qualitatively distinct modes of Sputnik V vaccine-neutralization escape by SARS-CoV-2 Spike variants. medRxiv. 2021. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8020991/
- Folegatti PM. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomized controlled trial. 2020; 396: 467-478.
- Forni G, Mantovani A, COVID-19 Commission of Accademia Nazionale dei Lincei, Rome. COVID-19 vaccines: where we stand and challenges ahead. Cell Death Differ. 2021; 28: 626–639. PubMed: https://pubmed.ncbi.nlm.nih.gov/33479399/
- Luisetto M, Almukhtar N, Hamid GA, Khan FA. Spike sars-cov-2 protein as procoagulant factor and vaccine class effect hypothesis. 2021. https://www.researchgate.net/publication/350721725_SPIKE_SARS-COV-2_PROTEIN_AS_PROCOAGULANT_FACTOR_AND_VACCINE_CLASS_EFFECT_HYPOTHESIS
- Dai L, Gao GF. Viral targets for vaccines against COVID-19. Nat Rev Immunol. 2020; 21: 73–82. PubMed: https://pubmed.ncbi.nlm.nih.gov/33340022/
- Tobaiqy M, Elkout H, MacLure K. Analysis of Thrombotic Adverse Reactions of COVID-19 AstraZeneca Vaccine Reported to Eudra Vigilance Database. Vaccines. 2021; 9: 393.
- Al-amri SS, Abbas AT, Siddiq LA, Alghamdi A, Sanki MA, et al. Immunogenicity of Candidate MERS-CoV DNA Vaccines Based on the Spike Protein. Scientific Reports. 2021; 7: 44875.
































